Clinical trials
Prostate Cancer Screening clinical trials
Below are recruiting prostate cancer screening clinical trials, each written for real people, not researchers. We’re tracking 319 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07569926RecruitingPhase 4
Fluciclovine PET scan for prostate cancer recurrence detection
This study tests whether a newer type of imaging scan (called fluciclovine PET) can find where prostate cancer has come back when an earlier scan (PSMA PET) didn't show clear results. The goal is to help doctors better plan treatment for men whose cancer has returned after surgery or radiation.
San Diego, CaliforniaAges 18 years+ - NCT07871435RecruitingPhase 1/Phase 2
Investigational combo for advanced prostate cancer
This trial tests two investigational drugs together for men with a type of advanced prostate cancer that has stopped responding to standard hormone therapy. The goal is to see if the combination can shrink tumors or slow the cancer's growth.
New York, New YorkAges 18 years+ - NCT07224009RecruitingPhase 2
Low dose naltrexone for fatigue in prostate cancer on hormone therapy
This trial tests if a low dose of the drug naltrexone can help reduce fatigue in men with prostate cancer who are currently receiving hormone therapy (ADT). It may offer a new way to manage tiredness during treatment.
Little Rock, ArkansasAges 18 years+ - NCT05348876RecruitingPhase 4
Darolutamide plus standard hormone therapy for high-risk prostate cancer
This trial studies how safe darolutamide is and how well it works when added to standard hormone therapy for men with high-risk, non-metastatic prostate cancer that is no longer responding to hormone treatment. It may help slow prostate cancer growth and reduce prostate-specific antigen (PSA) rises in real-world care.
Vijayawada, Andhra PradeshAges 18 years+ - NCT03972657RecruitingPhase 1/Phase 2
Testing a new prostate and kidney cancer drug with immunotherapy
This early trial tests whether REGN5678 (nezastomig) is safe and how well it works, either by itself or with an immunotherapy drug (cemiplimab). It targets adults with metastatic castration-resistant prostate cancer and certain metastatic kidney cancers that have already been treated.
Gilbert, ArizonaAges 18 years+ - NCT05000294RecruitingPhase 1/Phase 2
Atezolizumab plus tivozanib for hard-to-treat “cold” cancers
This early-stage study tests whether combining atezolizumab and tivozanib can shrink advanced, hard-to-treat cancers that do not strongly activate the immune system (“immunologically cold”). It is for people whose cancer has already been treated or has no good standard options.
Gainesville, FloridaAges 18–99 - NCT07660211RecruitingPhase 1
Radioactive treatment for advanced prostate cancer
This trial tests a radioactive treatment (177Lu-PSMA-VG01) that targets a protein called PSMA on prostate cancer cells. It's for men whose cancer has spread and hasn't gotten better with other treatments.
Shanghai, Shanghai MunicipalityAges 18–80 - NCT07311694RecruitingPhase 3
Comparing a new treatment with standard drugs for advanced prostate cancer
This trial tests a new drug, HRS-4357, against standard treatments for men with a specific type of advanced prostate cancer that has spread and no longer responds to hormone therapy. It aims to see if the new drug works better.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06863272RecruitingPhase 1/Phase 2
Study of ifinatamab deruxtecan for advanced prostate cancer
This trial tests a new drug, ifinatamab deruxtecan, either alone or in combination with other treatments, for men with metastatic castrate-resistant prostate cancer that has worsened despite hormone therapy. It aims to see if this approach can help shrink or slow the cancer.
Los Angeles, CaliforniaAges 18 years+ - NCT06594926RecruitingPhase 2
Bipolar androgen therapy for prostate cancer without metastases
This trial tests a treatment called bipolar androgen therapy for men with prostate cancer that has not spread to other parts of the body and is still growing despite taking darolutamide. The goal is to see if this therapy can help control the cancer.
Garran, Australian Capital TerritoryAges 18 years+ - NCT06282588RecruitingPhase 2/Phase 3
Advanced imaging-guided treatment for high-risk prostate cancer
This trial uses a special PET scan (PSMA PET/CT) and a genetic test (Decipher) to decide the best treatment for high-risk prostate cancer that hasn't spread outside the pelvis. You'll receive standard radiation and hormone therapy, possibly with an extra drug (darolutamide).
Wilrijk, AntwerpAges 18 years+ - NCT04916613RecruitingPhase 3
ADT plus darolutamide for vulnerable newly metastatic prostate cancer
This trial studies whether adding darolutamide to standard hormone therapy (ADT) helps men with newly diagnosed metastatic prostate cancer who are physically vulnerable. It aims to control the cancer better while checking safety and how well treatment is tolerated in this group.
CharleroiAges 18 years+ - NCT05983432RecruitingPhase 1
Study of BL-B01D1 for advanced lung and other solid tumors
This trial tests an experimental drug called BL-B01D1 for people with several types of advanced solid tumors, especially non-small cell lung cancer and breast cancer. It's designed for those whose cancer has continued to grow after standard treatments.
Beverly Hills, CaliforniaAges 18 years+ - NCT04969315RecruitingPhase 1/Phase 2
Study of two new drugs for advanced kidney, prostate, lung, or mesothelioma cancer
This study tests two new study drugs (TT-4 and TT-10) alone and together in people with certain advanced cancers that have not responded to standard treatments. The goal is to see if these drugs are safe and effective in shrinking tumors or slowing the cancer's growth.
Los Angeles, CaliforniaAges 18 years+ - NCT06482489Recruiting
Low-field MRI for better prostate imaging
This study tests a new, lower-strength MRI to see if it can give clearer images of the prostate, especially for men who have metal implants or who need a biopsy. It may help doctors monitor prostate health more safely and effectively.
Lausanne, Canton of VaudAges 18 years+ - NCT07594106RecruitingPhase 1/Phase 2
New immunotherapy for advanced prostate or kidney cancer
This trial tests new experimental drugs (REGN15505 and REGN4336) designed to target and attack cancer cells in advanced prostate cancer or kidney cancer. These drugs work by boosting your immune system to recognize and destroy cancer, and may be combined with other approved immunotherapy drugs.
Goodyear, ArizonaAges 18 years+ - NCT07543055RecruitingPhase 1
CAR T-Cell Therapy for Advanced Prostate Cancer
This trial tests BPX-601, a new type of cell therapy that uses your own immune cells to fight prostate cancer that has spread and stopped responding to hormone treatments. The study aims to see if this approach can help men whose cancer has returned despite multiple prior treatments.
Atlanta, GeorgiaAges 18 years+ - NCT06357416Recruiting
Man Van project: mobile cancer screening for men
This study collects information from men who visit the Man Van, a mobile health clinic that screens for cancers like prostate, testicular, and penile cancers. It aims to learn how well the clinic works and how it can help men catch cancer early.
LondonAges 18 years+ - NCT07052214RecruitingPhase 3
PSMA PET plus MRI to find prostate cancer
This trial tests if combining a PSMA PET scan with an MRI can better detect clinically significant prostate cancer than MRI alone. It may help men who have not had a prostate biopsy before and have certain risk factors.
Los Angeles, CaliforniaAges 18 years+ - NCT07226713RecruitingPhase 2
Pacritinib for advanced prostate cancer after hormone therapy failure
This trial tests a drug called pacritinib for men with metastatic prostate cancer that has stopped responding to hormone therapies. It aims to see if blocking the JAK2/STAT5 pathway can slow cancer growth.
Milwaukee, WisconsinAges 18 years+ - NCT06758882RecruitingPhase 2
Surgery with or without apalutamide for high-risk prostate cancer that has spread a little
This trial tests whether adding the drug apalutamide before and after surgery helps men with high-risk prostate cancer that has spread to a few spots (seen on a special PET scan). You would also receive standard hormone therapy.
Torino, ToAges 18–80 - NCT07333066RecruitingPhase 3
Adding chemotherapy when first treatment response is limited
This trial tests whether adding a chemotherapy drug (docetaxel) to your current treatment (apalutamide) can help control prostate cancer that has spread and hasn't responded as well as hoped to apalutamide alone.
BayonneAges 18 years+ - NCT06343038RecruitingPhase 1
A new targeted radiation drug for advanced prostate cancer
This trial tests a new radioactive drug (161Tb-SibuDAB) for men with metastatic prostate cancer that has grown despite standard treatments. It aims to find the right dose and see if it can shrink tumors.
BaselAges 18 years+ - NCT07543757Recruiting
Blood test to help decide if a prostate biopsy is needed
This study tests a new blood test (Proclarix) that may help doctors decide if a prostate biopsy is needed. It is for men with a slightly elevated PSA who are already considering a biopsy.
San Diego, CaliforniaAges 40–75
Hear when a new Prostate Cancer Screening trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for prostate cancer screening?
- Yes. Clin2 currently lists 319 recruiting prostate cancer screening studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a prostate cancer screening trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a prostate cancer screening trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.